🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

The one & only one Raffaella Casolino 🇺🇳 delivering the Keynote lecture at AIOM meeting in #Venice right now ! ✨ An illuminating perspective on #Cancer control amidst Humanitarian Challenges ✨ World Health Organization (WHO) #UHC Fondazione Aiom #LeGiornateDellEtica #SanServolo

The comprehensive perspective & philosophy of #migration , #health and #cancer in the spectacular lecture by Richard Sullivan at AIOM Happening now! #AIOM #LeGiornateDellEtica

Half of people with inherited BRCA1/2 mutations are men, yet very few men are offered genetic testing or know the importance to their own health. Article reviews data & screening recommendations aimed to help men take action to reduce their risk of cancer. ja.ma/3TV8WbG

INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC… I remember our 2015 meeting between CCTG and GI Cancer Institute and AGITG to design that trial, in beautiful Sydney.

The FDA Oncologic Drugs Advisory Committee on Sept. 26 voted that PD-L1 inhibitors should not be indicated as a first-line treatment for patients with PD-L1-negative gastric/gastroesophageal junction adenocarcinoma and esophageal squamous cell carcinoma. cancerletter.com/regulatory-new…

Adding to the ever growing approaches in GEA. Journal of Clinical Oncology ASCO. DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or GEJ Adenocarcinoma: DisTinGuish | ascopubs.org/doi/10.1200/JC…

Recently published 🔑 meta-analyses about ICIs in #gastric cancer according to #PDL1 by Lizzy Smyth Filippo Pietrantonio Raghav Sundar Joseph J Zhao ESMO - Eur. Oncology 🎯definitely to read and apply in clinical practice

@mddogdaddy Angelica Petrillo Filippo Pietrantonio Raghav Sundar Joseph J Zhao ESMO - Eur. Oncology The real world implication is that if another choice is available e.g. zolbetuximab then this should be considered.

OncologyEducation Filippo Pietrantonio OrigAMI-2 trial now listed on CTG A Study of Amivantamab &mFOLFOX6 or FOLFIRI Versus Cetuximab &mFOLFOX6 or FOLFIRI as First-line Treatment in Participants W/ KRAS/​NRAS & BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer NCT06662786 clinicaltrials.gov/study/NCT06662…

Cancers develop resistance to targeted therapies. Most studies on acquired resistance have focused on tumor cells and not the microenvironment. We outline spatial mechanisms of resistance to trastuzumab and TDxd in HER2+ Gastric Cancer. Filippo Pietrantonio medrxiv.org/content/10.110…

Honoured and thrilled to have been part of the educational session of gastroesophageal tumours at the #AIOM24 AIOM A very inclusive edition with a larger space for #youngoncologist (And babysitting)! 👏🏻and 🙏🏻 to the scientific committee!

Well said Richard Sullivan

Check out this clinically meaningful analysis by Lisa Salvatore & coworkers The Lancet Oncology

Describing a molecular subgroup with clinical implications, hopefully! Paolo Ciracì Vittorio Studiale Daniele Rossini

Special thanks to Raghav Sundar, Filippo Pietrantonio & team Part of the Emerging Frontiers in Advanced Gastroesophageal Cancer Special Collection, this research highlights critical advances. See the collection: journals.sagepub.com/topic/collecti…

The ARMANI trial is now online in The Lancet Oncology 🥰 TY to patients and my Team, and all the italian Investigators of this ph3 on ramucirumab plus paclitaxel as switch maintenance in advanced gastric cancer sciencedirect.com/science/articl…

This is the first solid evidence to show that cancer patients prefer certainty over speed of access to new cancer drugs. This directly challenges the current regulatory ecosystem. ESMO - Eur. Oncology ASCO FDA thelancet.com/journals/lanon…

The Prostaglandin EP4 Antagonist Vorbipiprant Combined with PD-1 Blockade for Refractory Microsatellite Stable Metastatic Colorectal Cancer: A Phase 1b/2a Trial aacrjournals.org/clincancerres/…

Tremelimumab and durvalumab as neoadjuvant or non-operative management of pts with MSI gastric cancer. First trial to show that these patients can live with their stomach after this diagnosis! sciencedirect.com/science/articl…

An incredible dr #Leone Università degli Studi di Milano presenting on patterns of inclusion & persisting barriers for access in clinical trials 4 patients wt #cancer & #HIV #PLWH Filippo Pietrantonio #ASCO25 ASCO AIOM